Biodesix (NASDAQ:BDSX) Posts Earnings Results, Beats Expectations By $0.56 EPS

Biodesix (NASDAQ:BDSX) issued its quarterly earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.56, Zacks reports. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. The business had revenue of $28.76 million during the quarter, compared to analyst estimates of $26.25 million.

Here are the key takeaways from Biodesix’s conference call:

• Biodesix reported strong Q4 and FY‑2025 results — total revenue of $28.8M in Q4 and $88.5M for the year, Q4 revenue up 41% YoY, gross margin improved to 83%, and the company achieved its first‑ever positive Adjusted EBITDA of $0.53M.
• Commercial traction accelerated with 18,000 Nodify tests in Q4 (+23% volume growth) and expansion into primary care now representing 12% of Nodify orders (up 67% YoY) after the company broadened its sales strategy beyond pulmonology.
• Management flagged that about $1M of Q4 revenue came from collections on claims older than one year and that typical Q1 seasonality and recent weather disruptions are expected to cause a near‑term step‑down in volumes and average revenue per test.
• 2026 guidance targets $106M–$112M in revenue (midpoint ~23% growth) with continued progress toward sustained Adjusted EBITDA positivity, supported by an expanded salesforce, higher ASPs, and operational leverage.
• The pipeline shows notable partnerships (including Thermo Fisher and Bio‑Rad) and multi‑omic/AI programs (MRD, VeriStrat expansions, ESR1 test), but management does not expect new commercial launches within 12 months and key trial readouts (e.g., ALTITUDE) are likely in 2027.

Biodesix Stock Performance

Shares of NASDAQ:BDSX traded up $1.11 during trading hours on Friday, hitting $15.33. The stock had a trading volume of 377,586 shares, compared to its average volume of 2,227,038. The stock’s fifty day simple moving average is $9.37 and its 200 day simple moving average is $8.32. Biodesix has a 1-year low of $3.44 and a 1-year high of $19.13. The firm has a market capitalization of $122.03 million, a price-to-earnings ratio of -2.76 and a beta of 0.67. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84.

Insider Activity at Biodesix

In related news, CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the sale, the chief executive officer directly owned 45,413 shares in the company, valued at $457,763.04. This trade represents a 7.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jack W. Schuler bought 82,465 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were acquired at an average cost of $10.96 per share, for a total transaction of $903,816.40. Following the purchase, the director directly owned 1,463,210 shares in the company, valued at $16,036,781.60. This represents a 5.97% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 182,465 shares of company stock valued at $2,084,616 and have sold 10,999 shares valued at $116,095. Insiders own 30.10% of the company’s stock.

Hedge Funds Weigh In On Biodesix

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BDSX. XTX Topco Ltd boosted its holdings in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares during the period. Cetera Investment Advisers purchased a new stake in shares of Biodesix in the 4th quarter valued at approximately $68,000. DRW Securities LLC acquired a new position in Biodesix in the 4th quarter worth approximately $105,000. Millennium Management LLC purchased a new position in Biodesix during the 3rd quarter worth approximately $113,000. Finally, State Street Corp raised its stake in Biodesix by 15.6% during the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after purchasing an additional 2,400 shares during the period. 20.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BDSX. William Blair raised shares of Biodesix from a “market perform” rating to an “outperform” rating in a research report on Friday. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 target price on shares of Biodesix in a research report on Tuesday, February 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Biodesix has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.